These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1007 related items for PubMed ID: 19884549

  • 41. Association Between Baseline Circulating Tumor Cells, Molecular Tumor Profiling, and Clinical Characteristics in a Large Cohort of Chemo-naïve Metastatic Colorectal Cancer Patients Prospectively Collected.
    Sastre J, Orden V, Martínez A, Bando I, Balbín M, Bellosillo B, Palanca S, Peligros Gomez MI, Mediero B, Llovet P, Moral VM, Viéitez JM, García-Alfonso P, Calle SG, Ortiz-Morales MJ, Salud A, Quintero G, Lopez C, Díaz-Rubio E, Aranda E, Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD).
    Clin Colorectal Cancer; 2020 Sep; 19(3):e110-e116. PubMed ID: 32278676
    [Abstract] [Full Text] [Related]

  • 42. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP, Piperdi B, Lacouture ME, Shearer H, Iannotti N, Pillai MV, Xu F, Yassine M.
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [Abstract] [Full Text] [Related]

  • 43. Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.
    Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT.
    J Clin Oncol; 2008 Jun 01; 26(16):2690-8. PubMed ID: 18509181
    [Abstract] [Full Text] [Related]

  • 44. Prognostic value of KRAS and BRAF mutations in curatively resected colorectal cancer.
    Kadowaki S, Kakuta M, Takahashi S, Takahashi A, Arai Y, Nishimura Y, Yatsuoka T, Ooki A, Yamaguchi K, Matsuo K, Muro K, Akagi K.
    World J Gastroenterol; 2015 Jan 28; 21(4):1275-83. PubMed ID: 25632202
    [Abstract] [Full Text] [Related]

  • 45. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
    Fornaro L, Baldi GG, Masi G, Allegrini G, Loupakis F, Vasile E, Cupini S, Stasi I, Salvatore L, Cremolini C, Vincenzi B, Santini D, Tonini G, Graziano F, Ruzzo A, Canestrari E, Magnani M, Falcone A.
    Crit Rev Oncol Hematol; 2011 Jun 28; 78(3):243-51. PubMed ID: 20619672
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 48. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
    Osumi H, Shinozaki E, Mashima T, Wakatsuki T, Suenaga M, Ichimura T, Ogura M, Ota Y, Nakayama I, Takahari D, Chin K, Miki Y, Yamaguchi K.
    Cancer Sci; 2018 Aug 28; 109(8):2567-2575. PubMed ID: 29908105
    [Abstract] [Full Text] [Related]

  • 49. Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer.
    Price TJ, Hardingham JE, Lee CK, Weickhardt A, Townsend AR, Wrin JW, Chua A, Shivasami A, Cummins MM, Murone C, Tebbutt NC.
    J Clin Oncol; 2011 Jul 01; 29(19):2675-82. PubMed ID: 21646616
    [Abstract] [Full Text] [Related]

  • 50. Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer.
    Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, De Gregorio V, Giannini R, Basolo F, Masi G, Falcone A.
    Int J Cancer; 2015 Jan 01; 136(1):83-90. PubMed ID: 24806288
    [Abstract] [Full Text] [Related]

  • 51. BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy.
    Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Wang HW, Chang SC, Lan YT, Lin CC, Wang HS, Yang SH.
    J Surg Oncol; 2012 Aug 01; 106(2):123-9. PubMed ID: 22331825
    [Abstract] [Full Text] [Related]

  • 52. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers.
    Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, Fuchs CS, Ogino S.
    Clin Cancer Res; 2012 Sep 01; 18(17):4753-63. PubMed ID: 22753589
    [Abstract] [Full Text] [Related]

  • 53. Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS.
    Kishiki T, Ohnishi H, Masaki T, Ohtsuka K, Ohkura Y, Furuse J, Watanabe T, Sugiyama M.
    Cancer Chemother Pharmacol; 2014 Apr 01; 73(4):749-57. PubMed ID: 24500024
    [Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. The role of K-RAS and B-RAF mutations as biomarkers in metastatic colorectal cancer.
    Selcukbiricik F, Erdamar S, Ozkurt CU, Molinas Mandel N, Demirelli F, Ozguroglu M, Tural D, Buyukunal E, Serdengecti S.
    J BUON; 2013 Apr 01; 18(1):116-23. PubMed ID: 23613396
    [Abstract] [Full Text] [Related]

  • 59. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E.
    PLoS One; 2015 Apr 01; 10(8):e0135599. PubMed ID: 26275292
    [Abstract] [Full Text] [Related]

  • 60. KRAS-mutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer.
    Spindler KG, Appelt AL, Pallisgaard N, Andersen RF, Jakobsen A.
    Br J Cancer; 2013 Dec 10; 109(12):3067-72. PubMed ID: 24263065
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 51.